Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

Escherichia coli DNA gyrase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (23) Antibiotic (20) Bacterial (37) Beta-lactamase (1) Drug Derivative (1) HCV (1) HCV Protease (1) Isotope-Labeled Compounds (4) Parasite (8) Reference Standards (6) Topoisomerase (22)
By Research Areas:	Cancer (1) Infection (37) Inflammation/Immunology (9)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: DNA-PK DNA Glycosylase DNA Methyltransferase DNA Stain DNA Alkylator/Crosslinker DNA/RNA Synthesis

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0398

Nalidixic acid 2 Publications Verification	Bacterial Antibiotic Topoisomerase	Infection
Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-B0147

Pefloxacin 3 Publications Verification Pefloxacinium	Antibiotic Bacterial Parasite DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-W011117

Danofloxacin	Bacterial DNA/RNA Synthesis Antibiotic	Infection
Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens .

HY-B0398A

Nalidixic acid sodium salt 2 Publications Verification	Bacterial Antibiotic Topoisomerase	Infection
Nalidixic acid sodium salt, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-N7066

Difloxacin hydrochloride A-56619 hydrochloride	Bacterial DNA/RNA Synthesis	Infection
Difloxacin hydrochloride (A-56619 hydrochloride) is an orally active bactericidal agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase. Difloxacin hydrochloride exhibits concentration-dependent bactericidal activity. Difloxacin hydrochloride shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin hydrochloride can be used in research related to colibacillosis and Staphylococcus aureus infections .

HY-B0147A

Pefloxacin mesylate 3 Publications Verification Pefloxacinium mesylate	Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) mesylate is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin mesylate inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate can be used for infection studies .

HY-N1341

Roseoside	HCV HCV Protease DNA/RNA Synthesis Bacterial	Infection
Roseoside is an inhibitor of DNA gyrase and HAV 3C protease, and also inhibits HCV NS5A/B replicase in human systems with an IC₅₀ of 20 μM. Roseoside binds to the active site of enzymes and stabilizes the interaction by forming hydrogen bonds with key amino acid residues. Roseoside inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, and Candida albicans, and interferes with HCV RNA replication in vitro by inhibiting HCV NS5A/B replicase (IC₅₀=20 μM). Roseoside shows no cytotoxicity and serves as a research tool for studies related to bacterial infections, candidiasis, HAV and HCV .

HY-123515

Clorobiocin		Infection
Clorobiocin is an antibacterial agent with an IC₅₀ of 0.21 μM against the B subunit of E. coli DNA gyrase. Clorobiocin targets the mLaC protein of Gram-negative bacteria. Clorobiocin potently inhibits bacterial DNA replication. Clorobiocin can be used in studies on Gram-negative bacterial infections, such as Acinetobacter baumannii and E. coli infections .

HY-177716

Ciprofloxacin prodrug-1	Beta-lactamase Bacterial	Infection
Ciprofloxacin prodrug-1 (Compound 35) is an activated prodrug of β-lactase. Ciprofloxacin prodrug-1 exhibits good antibacterial activity against bacteria containing β-lactase (MIC = 63 nM). After being hydrolyzed by β-lactase, Ciprofloxacin prodrug-1 can release Ciprofloxacin (HY-B0356), thereby inhibiting the activity of DNA gyrase. Ciprofloxacin prodrug-1 can be used to study infections caused by enzyme-producing drug-resistant bacteria (such as uropathogenic Escherichia coli) .

HY-108988

Albicidin	Antibiotic Bacterial Topoisomerase DNA/RNA Synthesis	Infection
Albicidin is a peptide antibiotic with phytotoxic activity. Albicidin potently inhibits bacterial and plant DNA gyrase at nanomolar concentrations, blocks DNA replication, and exhibits excellent antibacterial efficacy against multidrug-resistant bacteria. Albicidin possesses bactericidal activity against Gram-positive and Gram-negative microorganisms, and acts as a virulence factor for the systemic plant infection by Xanthomonas albilineans. Albicidin can be used in studies related to bacterial infections and sugarcane leaf blight .

HY-115990

Topoisomerase IV inhibitor 1	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 7d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC₅₀s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-B0147B

Pefloxacin mesylate dihydrate 3 Publications Verification Pefloxacinium mesylate dihydrate	Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) mesylate dihydrate is a broad spectrum antibiotic. Pefloxacin mesylate dihydrate blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin mesylate dihydrate inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate dihydrate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate dihydrate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate dihydrate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate dihydrate can be used for infection studies .

HY-101967

GSK299423	DNA/RNA Synthesis Bacterial	Infection
GSK 299423 is an antibiotic agent.GSK299423 shows potent inhibition of supercoiling by **DNA gyrase from S. aureus(IC₅₀*=14 nM）and Escherichia* coli(IC₅₀=100 nM .

HY-115991

Topoisomerase IV inhibitor 2	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 5d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC₅₀s of 0.35 μM and 0.55 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-117657

(-)-BO 2367	Topoisomerase Bacterial	Inflammation/Immunology Cancer
(-)-BO 2367, an antimicrobial quinolone, is a strong mammalian and bacterial topoisomerase II inhibitor. (-)-BO 2367 shows IC₅₀ values with 3.8 μM, 0.5 μM, and 1 μM against the DNA relaxation activity of L1210 topoisomerase II and the supercoiling activities of Escherichia coli gyrase and Micrococcus luteus gyrase, respectively. (-)-BO 2367 is a potent antitumor agent .

HY-B0398R

Nalidixic acid (Standard)	Reference Standards Bacterial Antibiotic Topoisomerase	Infection
Nalidixic acid (Standard) is the analytical standard of Nalidixic acid. This product is intended for research and analytical applications. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-170567

DNA gyrase/Topo IV-IN-1	Topoisomerase Bacterial Antibiotic	Infection
DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of **DNA gyrase and topoisomerase IV*, exhibiting antibacterial activity. For Escherichia* coli and methicillin-resistant Staphylococcus aureus DNA gyrases, DNA gyrase/Topo IV-IN-1 has an IC₅₀ of 11 and 17 nM respectively, and for topoisomerase IV of Escherichia coli and methicillin-resistant Staphylococcus aureus, the IC₅₀ values are 83 and 21 nM respectively. DNA gyrase/Topo IV-IN-1 can be used for research in the field of anti-infection .

HY-172962

DNA Gyrase-IN-17	DNA/RNA Synthesis Bacterial	Infection
DNA Gyrase-IN-17 (Compound 5C) is a **DNA Gyrase** inhibitor. DNA Gyrase-IN-17 exhibits significant antibacterial activity against a variety of Gram-positive and Gram-negative strains (such as Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, etc.), with a MIC value of 62.5 μg/mL. DNA Gyrase-IN-17 interferes with DNA replication by inhibiting bacterial DNA gyrase. DNA Gyrase-IN-17 can be used in the development of antibacterial drugs, especially for the study of drug-resistant strains .

HY-147948

DNA Gyrase-IN-4	DNA/RNA Synthesis Bacterial	Infection
DNA Gyrase-IN-4 (compound 8p) is a potent **DNA gyrase inhibitor, with an IC₅₀** of 0.13 μM. DNA Gyrase-IN-4 shows excellent antibacterial activity against Staphylococcus aureus, Listeria monocytogenes, Salmonella and Escherichia coli, with MIC values of 0.05, 0.05, 0.05, and 8 μg/mL, respectively .

HY-W011117S

Danofloxacin-d3	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis Antibiotic	Infection
Danofloxacin-d₃ is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-W011117S1

Danofloxacin-d3-1	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis Antibiotic	Infection
Danofloxacin-d3-1 is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-W011117R

Danofloxacin (Standard)	Reference Standards Bacterial DNA/RNA Synthesis Antibiotic	Infection
Danofloxacin (Standard) is the analytical standard of Danofloxacin. This product is intended for research and analytical applications. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-14780

Viquidacin NXL 101	Antibiotic Topoisomerase DNA/RNA Synthesis Bacterial	Infection
Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and **DNA gyrase*. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus* and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L .

HY-106940

DV-7751A	Bacterial DNA/RNA Synthesis	Infection
DV-7751A is a new Fluoroquinolone and antibacterial agent. DV-7751A inhibits the supercoiling activity of **DNA gyrases*. DV-7751A exhibits antimicrobial activity against Streptococcus pneumonae, Streptococcus pyogenes, and Peptostreptococcus* spp. DV-7751A has a rapid bactericidal effect against S. aureus, Escherichia coli, and P. aeruginosa .

HY-B0147S1

Pefloxacin-d3 Pefloxacinium-d₃	Isotope-Labeled Compounds Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin-d₃ (Pefloxacinium-d₃) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147S

Pefloxacin-d5 Pefloxacinium-d₅	Isotope-Labeled Compounds Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin-d₅ (Pefloxacinium-d₅) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147R

Pefloxacin (Standard) Pefloxacinium (Standard)	Reference Standards Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Standard) (Pefloxacinium (Standard)) is the analytical standard of Pefloxacin (HY-B0147). This product is intended for research and analytical applications. Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147AR

Pefloxacin mesylate (Standard) Pefloxacinium mesylate (Standard)	Reference Standards Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin mesylate (Standard) (Pefloxacinium mesylate (Standard)) is the analytical standard of Pefloxacin mesylate (HY-B0147A). This product is intended for research and analytical applications. Pefloxacin (Pefloxacinium) mesylate is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin mesylate inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate can be used for infection studies .

HY-B0147BR

Pefloxacin mesylate dihydrate (Standard) Pefloxacinium mesylate dihydrate (Standard)	Reference Standards Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) mesylate dihydrate (Standard) is the analytical standard of Pefloxacin mesylate dihydrate (HY-B0147B). This product is intended for research and analytical applications. Pefloxacin (Pefloxacinium) mesylate dihydrate is a broad spectrum antibiotic. Pefloxacin mesylate dihydrate blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin mesylate dihydrate inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate dihydrate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate dihydrate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate dihydrate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate dihydrate can be used for infection studies .

HY-113718

DS21412020	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin (HY-121544)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics .

HY-B0398AR

Nalidixic acid sodium salt (Standard)	Reference Standards Bacterial Antibiotic Topoisomerase	Infection
Liquiritin (Standard) is the analytical standard of Liquiritin. This product is intended for research and analytical applications. Liquiritin, a flavonoid isolated from Glycyrrhiza uralensis, is a potent and competitive AKR1C1 inhibitor with IC50s of 0.62 μM, 0.61 μM, and 3.72μM for AKR1C1, AKR1C2 and AKR1C3, respectively. Liquiritin efficiently inhibits progesterone metabolism mediated by AKR1C1 in vivo . Liquiritin acts as an antioxidant and has neuroprotective, anti-cancer and anti-inflammatory activity .

HY-B0395E

(1S,2R,7S)-Sitafloxacin (1S,2R,7S)-DU-6859a; DU-6856	Antibiotic Bacterial Topoisomerase	Infection
(1S,2R,7S)-Sitafloxacin (DU-6856) is an enantiomer of Sitafloxacin (HY-B0395). (1S,2R,7S)-Sitafloxacin is a topoisomerase inhibitor. (1S,2R,7S)-Sitafloxacin is an antibiotic. (1S,2R,7S)-Sitafloxacin has inhibitory activity against Escherichia coli DNA gyrase (IC50 0.18 μg/mL) and Staphylococcus aureus topoisomerase IV. (1S,2R,7S)-Sitafloxacin has antibacterial activity and can be used in the study of various bacterial infections .

HY-181819

Antibacterial agent 327	Bacterial Topoisomerase	Infection
Antibacterial agent 327 (Compound 6f) is an Antibacterial agent. Antibacterial agent 327 potently inhibits the supercoiling activity of Staphylococcus aureus DNA gyrase with an IC₅₀ of 0.28 μM. It also inhibits the ATPase activities of **DNA gyrase and Topoisomerase IV, as well as the decatenation activity of Topoisomerase IV (IC₅₀*: 0.43 μM, 0.73 μM, and 2.31 μM, respectively). Antibacterial agent 327 potently inhibits Clostridioides difficile* and methicillin-resistant Staphylococcus aureus (HY-121544), with an MIC of 0.78 μg/mL for both. Antibacterial agent 327 inhibits Escherichia coli with an MIC₅₀ of 0.78 μg/mL .

HY-183700

DNA gyrase/Topo IV-IN-3	DNA/RNA Synthesis Topoisomerase Bacterial	Infection
DNA gyrase/Topo IV-IN-3 is an inhibitor of Escherichia coli **DNA gyrase and Topoisomerase IV, with IC₅₀** values of 1.75 μM and 3.47 μM, respectively. DNA gyrase/Topo IV-IN-3 acts as a biofilm inhibitor and exhibits antibacterial activity against both Gram-negative and Gram-positive bacteria. DNA gyrase/Topo IV-IN-3 can be used in studies related to bacterial infections .

HY-183712

Antibacterial agent 345	Bacterial DNA/RNA Synthesis Drug Derivative	Infection
Antibacterial agent 345 is a Ciprofloxacin (HY-B0356)-lipophilic derivative and is an antibacterial agent. Antibacterial agent 345 inhibits DNA gyrase and inhibits bacterial DNA replication and transcription. Antibacterial agent 345 inhibits bacterial biofilm formation. Antibacterial agent 345 can be used for the research of bacterial infections, such as Pseudomonas aeruginosa infection .

HY-116558

E-4441	Bacterial	Infection
E-4441 is an orally active Antibacterial agent. E-4441 exerts broad-spectrum in vitro antibacterial activity against Gram-positive bacteria and aerobic bacteria. E-4441 exhibits protective effects against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa infections. E-4441 can be used in the research of systemic bacterial infections (Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa infections) .

HY-W683763A

Olamufloxacin methanesulfonate HSR-903	Bacterial	Infection
Olamufloxacin (HSR-903) methanesulfonate is an orally active fluoroquinolone antibacterial agent. Olamufloxacin methanesulfonate inhibits DNA supercoiling activity. Olamufloxacin methanesulfonate exhibits activity against Gram-positive, Gram-negative, chlamydial, and quinolone-resistant bacterial strains. Olamufloxacin methanesulfonate can be used for the research of bacterial infections .

HY-W683763

Olamufloxacin HSR-903 free base	Bacterial	Infection
Olamufloxacin (HSR-903) is an orally active fluoroquinolone antibacterial agent. Olamufloxacin inhibits DNA supercoiling activity. Olamufloxacin exhibits activity against Gram-positive, Gram-negative, chlamydial, and quinolone-resistant bacterial strains. Olamufloxacin can be used for the research of bacterial infections .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0398

Nalidixic acid 2 Publications Verification	Infection Microorganisms Classification of Application Fields Antibiotics Resistance Selection Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Bacterial Antibiotic Topoisomerase
Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-B0147

Pefloxacin 3 Publications Verification Pefloxacinium	Infection Classification of Application Fields Disease Research Fields	Antibiotic Bacterial Parasite DNA/RNA Synthesis Topoisomerase
Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0398R

Nalidixic acid (Standard)	Structural Classification Microorganisms Antibiotics Resistance Selection Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards Bacterial Antibiotic Topoisomerase
Nalidixic acid (Standard) is the analytical standard of Nalidixic acid. This product is intended for research and analytical applications. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

Cat. No.	Product Name	Chemical Structure

HY-W011117S

Danofloxacin-d3
Danofloxacin-d₃ is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-W011117S1

Danofloxacin-d3-1
Danofloxacin-d3-1 is deuterium labeled Danofloxacin. Danofloxacin is an orally active quinolone antibiotic. Danofloxacin targets bacterial DNA gyrase and inhibits bacterial DNA replication, transcription and growth. Danofloxacin can be used for various bacterial infections caused by Escherichia coli, Mycoplasma and other pathogens.

HY-B0147S1

Pefloxacin-d3
Pefloxacin-d₃ (Pefloxacinium-d₃) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting **DNA gyrase*. Pefloxacin inhibits DNA* relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

Pefloxacin-d3

Pefloxacin-d₃ (Pefloxacinium-d₃) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147S

Pefloxacin-d5

Pefloxacin-d₅ (Pefloxacinium-d₅) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks